Abstract
Epilepsy is the most common chronic neurologic disorder in the world, affecting 1-2% of the population. Besides, 30% of epilepsy patients are drug-resistant. Genomic mutations seem to play a key role in its etiology and knowledge of strong effect mutations in protein structures might improve prediction and the development of efficacious drugs to treat epilepsy. Several genetic association studies have been undertaken to examine the effect of a range of candidate genes for resistance. Although, few studies have explored the effect of the mutations into protein structure and biophysics in the epilepsy field. Much work remains to be done, but the plans made for exciting developments will hold therapeutic potential for patients with drug-resistance. In summary, we provide a critical review of the perspectives for the development of individualized medicine for epilepsy based on genetic polymorphisms/mutations in light of core elements such as transcriptomics, structural biology, disease model, pharmacogenomics and pharmacokinetics in a manner to improve the success of trial designs of antiepileptic drugs.
Keywords: Genetic epilepsy, brain organoids, transcriptome, single-cell sequencing, pharmacogenomics, drug resistance, drug development, antiepileptic drugs.
Current Neuropharmacology
Title:Personalized Medicine Using Cutting Edge Technologies for Genetic Epilepsies
Volume: 19 Issue: 6
Author(s): Sheila Garcia-Rosa, Bianca de Freitas Brenha, Vinicius Felipe da Rocha, Ernesto Goulart and Bruno Henrique Silva Araujo*
Affiliation:
- Brazilian Biosciences National Laboratory (LNBio), Center for Research in Energy and Material (CNPEM), Campinas, SP,Brazil
Keywords: Genetic epilepsy, brain organoids, transcriptome, single-cell sequencing, pharmacogenomics, drug resistance, drug development, antiepileptic drugs.
Abstract: Epilepsy is the most common chronic neurologic disorder in the world, affecting 1-2% of the population. Besides, 30% of epilepsy patients are drug-resistant. Genomic mutations seem to play a key role in its etiology and knowledge of strong effect mutations in protein structures might improve prediction and the development of efficacious drugs to treat epilepsy. Several genetic association studies have been undertaken to examine the effect of a range of candidate genes for resistance. Although, few studies have explored the effect of the mutations into protein structure and biophysics in the epilepsy field. Much work remains to be done, but the plans made for exciting developments will hold therapeutic potential for patients with drug-resistance. In summary, we provide a critical review of the perspectives for the development of individualized medicine for epilepsy based on genetic polymorphisms/mutations in light of core elements such as transcriptomics, structural biology, disease model, pharmacogenomics and pharmacokinetics in a manner to improve the success of trial designs of antiepileptic drugs.
Export Options
About this article
Cite this article as:
Garcia-Rosa Sheila , de Freitas Brenha Bianca , da Rocha Felipe Vinicius , Goulart Ernesto and Silva Araujo Henrique Bruno *, Personalized Medicine Using Cutting Edge Technologies for Genetic Epilepsies, Current Neuropharmacology 2021; 19 (6) . https://dx.doi.org/10.2174/1570159X18666200915151909
DOI https://dx.doi.org/10.2174/1570159X18666200915151909 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
Call for Papers in Thematic Issues
Advances in paediatric and adult brain cancers: emerging targets and treatments
Brain tumors are the most common solid tumors affecting children and adolescents, with up to 5,000 children diagnosed per year. Pediatric brain tumors, because of their location, are often untreatable and their clinical management can cause significant long-term impairment to intellectual and neurological function with epilepsy and neurodegeneration. Other than ...read more
Emotion (dys)regulation: an integration of pharmacological, neurobiological and psychologicalframeworks
Emotion regulation is a critical aspect of mental well-being and interpersonal relationships. To fully understand and effectively address emotion regulation, an integrative approach that considers pharmacological, neurobiological, and psychological frameworks is essential. Pharmacological interventions, such as medications targeting neurotransmitter imbalances, can play a significant role in managing emotional dysregulation. Understanding ...read more
Intercellular Communications in cerebral ischemia
Cerebral ischemia, a condition in which there is inadequate blood supply to the brain, ranks as one of the leading causes of disability and mortality globally. Despite its prevalence and severity, efficacious treatment options for this debilitating disorder remain limited. Recent scientific explorations have delved deeply into the pathological mechanisms ...read more
Microbiota- Gut - Brain Axis in mood and neuropsychiatric disorders. Therapeutic opportunities
The researches of the last two decades indicate that the role of the intestinal system can be fundamental in most diseases. The bidirectional Microbiota - Gut –Brain - Axis (MGBA) includes the central nervous system (CNS), the autonomic nervous system (ANS), the vagus nerve, the neuroendocrine system, neuroimmune systems, the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ursolic Acid: Historical Aspects to Promising Pharmacological Actions for
the Treatment of Central Nervous System Diseases
Current Cosmetic Science Preparation, Characterization and in vivo Evaluation of Simple Monolithic Ethylcellulose-coated Pellets Containing Topiramate with Biphasic Release Characteristics
Current Drug Delivery Roles of TRAF6 in Central Nervous System
Current Neuropharmacology Therapeutic Targets for the Management of Peripheral Nerve Injury- Induced Neuropathic Pain
CNS & Neurological Disorders - Drug Targets The Role of Ionotropic Glutamate Receptors in Childhood Neurodevelopmental Disorders: Autism Spectrum Disorders and Fragile X Syndrome
Current Neuropharmacology Editorial (Adverse Effects, Adverse Events and Side-Effects: Does the Terminology Matter?
Current Drug Safety mTOR Inhibitors in Tuberous Sclerosis Complex
Current Neuropharmacology Neuroimaging Findings in a Series of Children with Cerebral Palsy and Congenital Cytomegalovirus Infection
Infectious Disorders - Drug Targets Resveratrol in Medicinal Chemistry: A Critical Review of its Pharmacokinetics, Drug-Delivery, and Membrane Interactions
Current Medicinal Chemistry Migraine and Central Sensitization: Clinical Features, Main Comorbidities and Therapeutic Perspectives
Current Rheumatology Reviews Novel Medication Targets for the Treatment of Alcoholism: Preclinical Studies
Recent Patents on CNS Drug Discovery (Discontinued) Editorial:Cannabis: Neurological Correlates in Abuse and Medical Use
CNS & Neurological Disorders - Drug Targets Ultra-micronized Palmitoylethanolamide: An Efficacious Adjuvant Therapy for Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Bipolar Affective Disorder in Young People: A Review
Adolescent Psychiatry Brain Tumor Causes, Symptoms, Diagnosis and Radiotherapy Treatment
Current Medical Imaging Nutraceuticals, A New Challenge for Medicinal Chemistry
Current Medicinal Chemistry Metabolic Ataxias in Adults
Current Molecular Medicine Cardiac Monitoring in Patients with Syncope: Making that Elusive Diagnosis
Current Cardiology Reviews Functional Interference of Dexamethasone on Some Morphine Effects:Hypothesis for the Steroid-Opioid Interaction
Recent Patents on CNS Drug Discovery (Discontinued) Editorial [Hot Topic: Nitric Oxide: Implications for the Etiology & Treatment of Central Nervous System Disorders (Guest Editor: Giuseppe Di Giovanni)]
CNS & Neurological Disorders - Drug Targets